CoreLab Partners
will showcase several new technological solutions to coincide with the upcoming DIA meeting in Chicago, Illinois to be held from June 20 - 23, 2011.
“I am pleased to announce that as a part of an on-going commitment to our sponsor partners to deliver the highest possible quality through a cost effective, technologically driven process, we are positioned to launch another series of enabling solutions in both our ImagEngine SM and WebHeart platforms”, said CoreLab Partners’ President and CEO, Dr. Mike Woehle . “Our proprietary advanced imaging application, ImagEngineSM, will perform 3D and volumetric measurements while incorporating multi-planer reconstruction tools with lesion propagation which will expand our therapeutic reach and addresses the growing needs for this type of image analysis going forward,” added Woehler.
CoreLab Partners invites you to learn more about their comprehensive suite of service capabilities and new technological solutions at booth #1035 at the 47th Annual DIA meeting in Chicago, Illinois.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.